Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor
ctDNA kinetics, assessed with a tumor-informed assay, can predict anti-PD-1 therapy efficacy in R/M SCCHN. Early ctDNA clearance during the initial weeks of immunotherapy seems to be a strong predictive marker for a favorable response, as well as improved PFS and OS.
Authors
- Vasily N. Aushev (ORCID: https://orcid.org/0000-0001-8003-358X)
- Minetta C. Liu (ORCID: https://orcid.org/0000-0002-8206-5232)
- George Laliotis (ORCID: https://orcid.org/0000-0001-9205-8258)
- Sharlene Velichko (ORCID: https://orcid.org/0000-0002-0133-100X)
- Hajar Dahou (ORCID: https://orcid.org/0009-0001-4479-5760)
- Natasha Honoré (ORCID: https://orcid.org/0009-0007-0684-9143)
- Jean‐Pascal Machiels (ORCID: https://orcid.org/0000-0001-6369-9742)
- Charuta C. Palsuledesai (ORCID: https://orcid.org/0000-0002-3850-260X)
- Rachel Galot (ORCID: https://orcid.org/0000-0002-0596-4752)
- Cédric van Marcke (ORCID: https://orcid.org/0000-0003-3454-0630)
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- de Duve Institute (BE)
- Natera (United States) (US)
- University of the Incarnate Word (US)
- UCLouvain (BE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1309
- Citations
- 3
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 2.81